For Patients

Through a simple blood draw, the PrecivityAD2® test determines your likelihood (positive or negative) for the presence of amyloid plaques in the brain, one of the brain pathology findings of Alzheimer’s disease.

Who are the tests for?

According to the National Institute on Aging, numerous benefits exist to participating in a clinical trial.

THE NATIONAL INSTITUTE ON AGING LISTS THE SIGNS OF MCI AS:

  • Losing things often
  • Forgetting to go to events or appointments
  • Having more trouble coming up with words than other people of the same age

For more information on MCI, please visit: National Institute on Aging (nih.gov). Check with your health care provider to determine if a PrecivityAD2® test is right for you.

Score Interpretation

The following lists the interpretation of the algorithm’s score:

Step 1

Your health care provider orders the PrecivityAD2® test and schedules a blood draw appointment.

Step 2

Your blood sample is sent to the C2N laboratory for analysis.

Step 3

Your health care provider receives the PrecivityAD2® test report and interprets the positive or negative test result along with other medical information about you. Your provider will then discuss your report with you, answer any questions, and discuss the next steps in your care and management.

Like other tests that evaluate for brain amyloid pathology in clinical patients [such as amyloid PET scan or cerebrospinal fluid (CSF) testing] the Precivity® blood tests by themselves do not diagnose Alzheimer’s disease. Healthcare professionals interpret the test results along with other medical information.

Understanding Your Results

The PrecivityAD2® blood test or the PrecivityAD® blood test will tell your healthcare professional your likelihood for having changes in the brain associated with Alzheimer’s disease.

PrecivityAD2®

The main test result of the PrecivityAD2® blood test is a score called the Amyloid Probability Score 2 (APS2), which determines a patient’s likelihood (positive or negative) for presence of amyloid plaques in the brain.

Precivity-ApoE®

The Precivity-ApoE® blood test reports a patient’s ApoE protein types (E2, E3, or E4) to determine APOE status which may be useful for decision-making about treatment options.

An early diagnosis helps a researcher continue doing the work he loves.

The information presented on or through this document and any accompanying communications are made available solely for general information purposes. This information is not intended to provide medical advice or health care advice nor is it intended to be relied on for medical diagnosis or treatment. Always seek the advice of a physician or other qualified health care provider concerning questions or concerns that you have regarding a medical condition, treatment or test. Do not disregard any medical advice or postpone obtaining medical advice due to any information you have read on or through this document or any accompanying communications. For the full Disclaimer Statement, see Terms of Use document on www.PrecivityAD2.com.